title: Nutrition and pancreatic enzyme intake in patients with cystic fibrosis with distal intestinal obstruction syndrome.
abstract: BACKGROUND
  The etiology of distal intestinal obstruction syndrome (DIOS) remains unclear. Food intake and pancreatic enzyme replacement therapy (PERT) are often blamed for its occurrence. This study evaluates the nutrition intake and PERT of patients with cystic fibrosis (CF) at a first episode of DIOS.
  
  
  METHODS
  All patients with CF perform annually a 3-day intake diary to evaluate their caloric, protein, fat, dietary fiber, liquid, and PERT intake. Patients diagnosed with a first episode of DIOS (n = 12) retrospectively completed an intake diary of the 3 days preceding the DIOS episode supervised by an expert dietitian. RESULTS were compared with those of 1 year before and also with 36 CF controls matched for age, sex, genotype, and disease severity. All were pancreatic insufficient.
  
  
  RESULTS
  A first DIOS episode was diagnosed in 12 patients with CF. Only the absolute median fat intake (P = .015) and pancreatic enzyme intake (P = .035) were higher at the time of the DIOS attack in comparison to the preceding year. This could result from the difference in data collection or from the recommendations to increase fat intake and concomitant enzyme intake, since this trend was also found in the control group. The significant difference disappears when enzyme intake is expressed as units of lipase/g of fat. No other significant dietary differences were found.
  
  
  CONCLUSIONS
  This study provides no indications for a potential role of nutrition factors or pancreatic enzymes in the first occurrence of DIOS.
authors.affiliation: Cystic Fibrosis Centre, Department of Paediatrics, Ghent University Hospital, Belgium dimitri.declercq@uzgent.be.
authors.forename: Dimitri
authors.initials: D
authors.lastname: Declercq
authors.affiliation: Cystic Fibrosis Centre, Department of Paediatrics, Ghent University Hospital, Belgium.
authors.forename: Stephanie
authors.initials: S
authors.lastname: Van Biervliet
authors.affiliation: Cystic Fibrosis Centre, Department of Paediatrics, Ghent University Hospital, Belgium.
authors.forename: Eddy
authors.initials: E
authors.lastname: Robberecht
mesh_terms: D000293:Adolescent; D000328:Adult; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D003550:Cystic Fibrosis / Q000150:complications* / Q000178:diet therapy; D004041:Dietary Fats / Q000008:administration & dosage; D004435:Eating; D056947:Enzyme Replacement Therapy / Q000379:methods*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007415:Intestinal Obstruction / Q000178:diet therapy* / Q000209:etiology*; D008049:Lipase / Q000008:administration & dosage / Q000097:blood; D008297:Male; D009752:Nutritional Status; D010179:Pancreas / Q000201:enzymology*; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D004041:Dietary Fats; D008049:Lipase
keywords: cystic fibrosis; distal intestinal obstruction syndrome; exocrine pancreatic insufficiency; nutrition therapy; pancreatic enzyme replacement therapy; pancrelipase